Atorvastatin in Factorial with Omega-3 Fatty Acids Risk Reduction in Diabetes
OVERVIEW
The Atorvastatin in Factorial with Omega-3 fatty acids Risk Reduction in Diabetes (AFORRD) study was a one-year, community-based, multi-centre, randomised controlled trial assessing the degree to which a statin and/or omega-3 fatty acids reduce the estimated risk of coronary heart disease (CHD) in 1,000 people with Type 2 diabetes.
RESULTS
The results of the AFORRD trial were presented at the International Diabetes Federation Congress in Cape Town on Thursday 7th December 2006